Serum transfer RNA‐derived fragment tRF‐31‐79MP9P9NH57SD acts as a novel diagnostic biomarker for non‐small cell lung cancer. Issue 7 (16th May 2022)

• Record Type: Journal Article
• Authors: Li, Jipeng; Cao, Chao; Fang, Laifu; Yu, Wanjun
• Is Part Of: Journal of clinical laboratory analysis. Volume 36:Issue 7(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-16
• Subjects: biomarker -- NSCLC -- tRF‐31‐79MP9P9NH57SD -- tRNA‐derived small RNAs; Diagnosis, Laboratory -- Periodicals; Medical laboratory technology -- Periodicals; 616
• DOI: 10.1002/jcla.24492
• Languages: English
• ISSNs: 0887-8013

Abstract

Abstract: Background: tRNA‐derived fragments (tRFs) have been found to have a crucial function in the pathophysiology of cancers. However, the function of tRFs in non‐small cell lung cancer (NSCLC) is yet unknown. The goal of this study was to assess the tRF‐31‐79MP9P9NH57SD serum expression from NSCLC patients and to determine its diagnostic usefulness. Methods: By using stem‐loop quantitative real‐time PCR, we were able to detect various tRF‐31‐79MP9P9NH57SD expressions in 96 NSCLC serum samples, 96 healthy controls, and 20 pairs of NSCLC serum samples pre‐ and post‐surgery (qRT‐PCR). After that, we analyzed its diagnostic effectiveness using the receiver operating characteristic (ROC) curve. Results: Serum tRF‐31‐79MP9P9NH57SD expression was higher in NSCLC patients, and levels of tRF‐31‐79MP9P9NH57SD were linked to the clinical stage ( p = 0.002) and the malignancy of lymph node ( p = 0.012). In addition, after the procedure, the serum tRF‐31‐79MP9P9NH57SD expression in NSCLC patients dropped. With 48.96 percent sensitivity and 90.62 percent specificity, the area under ROC curve (AUC) was 0.733. Conclusion: serum tRF‐31‐79MP9P9NH57SD possibly is a new and groundbreaking biomarker for the NSCLC. Abstract : Serum levels of tRF‐31‐79MP9P9NH57SD were detected in NSCLC by stem‐loop qRT‐PCR. Then clinical implications and downstream targets of tRF‐31‐79MP9P9NH57SD were analyzed.